Expanding TIL Clinical Activity Beyond Melanoma by Selectively Enriching Tumor Reactive T-cells
- Demonstrating clinical feasibility of isolating tumor reactive T-cells across multiple solid tumor types
- Sharing early phase safety and response observations from a selective TIL approach
- Informing future trial design by linking cell composition to clinical outcomes